900000000000509007: United States of America English language reference set (foundation metadata concept)

SNOMED CT Concept\SNOMED CT Model Component\Foundation metadata concept (foundation metadata concept)\Reference set\Language type reference set (foundation metadata concept)\English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)\US English

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 01-Jul 2024. Module: IPS terminology module (core metadata concept)

Descriptions:

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
US English	Is a	English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)	true	Inferred relationship	Some

Members	acceptabilityId
Product containing precisely ivermectin 3 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely ketamine (as ketamine hydrochloride) 50 milligram/1 milliliter conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lactulose 667 milligram/1 milliliter conventional release oral solution (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lactulose 670 milligram/1 milliliter conventional release oral solution (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamivudine 10 milligram/1 milliliter conventional release oral solution (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamivudine 150 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamivudine 30 milligram and zidovudine 60 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamotrigine 100 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamotrigine 100 milligram/1 each conventional release orodispersible tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamotrigine 2 milligram/1 each conventional release chewable tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamotrigine 200 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamotrigine 200 milligram/1 each conventional release orodispersible tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamotrigine 25 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamotrigine 25 milligram/1 each conventional release orodispersible tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamotrigine 5 milligram/1 each conventional release chewable tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamotrigine 50 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lamotrigine 50 milligram/1 each conventional release orodispersible tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely latanoprost 50 microgram/1 milliliter conventional release eye drops (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely ledipasvir 90 milligram and sofosbuvir 400 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lenalidomide 25 milligram/1 each conventional release oral capsule (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely leuprorelin acetate 60 milligram/1 milliliter conventional release suspension for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely leuprorelin acetate 7.5 milligram/1 milliliter conventional release suspension for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levamisole (as levamisole hydrochloride) 150 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levamisole (as levamisole hydrochloride) 50 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levofloxacin 100 milligram/1 each tablet for conventional release oral suspension (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levofloxacin 250 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levofloxacin 500 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levofloxacin 750 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levonorgestrel 1.5 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levonorgestrel 30 microgram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levonorgestrel 75 milligram/1 each prolonged-release subcutaneous implant (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levonorgestrel 750 microgram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levonorgestrel 833 nanogram/1 hour prolonged-release intrauterine drug delivery system (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levothyroxine sodium anhydrous 100 microgram/1 each conventional release oral capsule (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levothyroxine sodium anhydrous 100 microgram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levothyroxine sodium anhydrous 25 microgram/1 each conventional release oral capsule (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levothyroxine sodium anhydrous 25 microgram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levothyroxine sodium anhydrous 50 microgram/1 each conventional release oral capsule (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely levothyroxine sodium anhydrous 50 microgram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lidocaine hydrochloride 10 milligram/1 milliliter conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lidocaine hydrochloride 20 milligram/1 gram conventional release cutaneous gel (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lidocaine hydrochloride 20 milligram/1 milliliter conventional release cutaneous solution (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lidocaine hydrochloride 20 milligram/1 milliliter conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lidocaine hydrochloride 40 milligram/1 milliliter conventional release cutaneous solution (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely linezolid 100 milligram/1 each tablet for conventional release oral suspension (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely linezolid 2 milligram/1 milliliter conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely linezolid 20 milligram/1 milliliter conventional release oral suspension (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely linezolid 400 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely linezolid 600 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lithium carbonate 300 milligram/1 each conventional release oral capsule (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lithium carbonate 300 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lithium citrate 104 milligram/1 milliliter conventional release oral solution (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely loperamide hydrochloride 2 milligram/1 each conventional release oral capsule (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely loperamide hydrochloride 2 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lopinavir 100 milligram and ritonavir 25 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lopinavir 200 milligram and ritonavir 50 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lopinavir 40 milligram and ritonavir 10 milligram/1 each conventional release oral capsule (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lopinavir 80 milligram/1 milliliter and ritonavir 20 milligram/1 milliliter conventional release oral solution (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely loratadine 1 milligram/1 milliliter conventional release oral solution (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely loratadine 10 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lorazepam 2 milligram/1 milliliter conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lorazepam 4 milligram/1 milliliter conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely losartan potassium 100 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely losartan potassium 25 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely losartan potassium 50 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lovastatin 10 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lovastatin 20 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely lovastatin 40 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely magnesium sulfate heptahydrate 500 milligram/1 milliliter conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mannitol 100 milligram/1 milliliter conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mannitol 200 milligram/1 milliliter conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mebendazole 100 milligram/1 each conventional release chewable tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mebendazole 500 milligram/1 each conventional release chewable tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely medroxyprogesterone acetate 150 milligram/1 milliliter conventional release suspension for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely medroxyprogesterone acetate 160 milligram/1 milliliter conventional release suspension for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely medroxyprogesterone acetate 5 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mefloquine (as mefloquine hydrochloride) 250 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely meglumine antimoniate 300 milligram/1 milliliter conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely melarsoprol 36 milligram/1 milliliter conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely melphalan (as melphalan hydrochloride) 50 milligram/1 vial powder for conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely melphalan 2 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mercaptopurine 50 milligram/1 each conventional release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely meropenem 1 gram and vaborbactam 1 gram/1 vial powder for conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely meropenem 1 gram/1 vial powder for conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely meropenem 500 milligram/1 vial powder for conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mesalazine 1 gram/1 each conventional release rectal suppository (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mesalazine 1 gram/1 each gastro-resistant and prolonged-release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mesalazine 1 gram/1 sachet gastro-resistant and prolonged-release oral granules (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mesalazine 1.2 gram/1 each gastro-resistant and prolonged-release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mesalazine 2 gram/1 sachet gastro-resistant and prolonged-release oral granules (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mesalazine 250 milligram/1 each conventional release rectal suppository (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mesalazine 250 milligram/1 each gastro-resistant and prolonged-release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mesalazine 4 gram/1 sachet gastro-resistant and prolonged-release oral granules (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mesalazine 400 milligram/1 each gastro-resistant and prolonged-release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mesalazine 500 milligram/1 each conventional release rectal suppository (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mesalazine 500 milligram/1 each gastro-resistant and prolonged-release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mesalazine 66.7 milligram/1 milliliter conventional release rectal suspension (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mesalazine 800 milligram/1 each gastro-resistant and prolonged-release oral tablet (clinical drug)	Preferred (foundation metadata concept)
Product containing precisely mesna 100 milligram/1 milliliter conventional release solution for injection (clinical drug)	Preferred (foundation metadata concept)

Start Previous Page 410 of 579 Next End

Reference Sets

Reference set descriptor

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
900000000001115012	United States of America English language reference set	en	Synonym (core metadata concept)	Active	Entire term case sensitive (core metadata concept)	IPS terminology module (core metadata concept)
900000000001116013	US English	en	Synonym (core metadata concept)	Active	Entire term case sensitive (core metadata concept)	IPS terminology module (core metadata concept)
900000000001117016	United States of America English language reference set (foundation metadata concept)	en	Fully specified name	Active	Entire term case sensitive (core metadata concept)	IPS terminology module (core metadata concept)